ESR1 and breast carcinoma: The suppression of PI3K signaling in ER-positive, PIK3CA-mutated breast cancer cell lines resulted in the induction of ER-dependent transcriptional activity, which were enhanced by the addition of estradiol and suppressed using the anti-ER therapies fulvestrant and tamoxifen [56].